278 related articles for article (PubMed ID: 31836141)
1. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
2. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
3. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
5. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
6. Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
Ma L; Xu Y; Xu X
Biochem Biophys Res Commun; 2020 Aug; 529(3):622-628. PubMed ID: 32736683
[TBL] [Abstract][Full Text] [Related]
7. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
11. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
12. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
13. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
14. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
16. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
20. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
